Preliminary results from a Phase 1 study show that the developmental drug ARRY-614 may be effective and safe for lower-risk myelodysplastic syndromes patients who have failed other therapies.
Dr. Rami Komrokji of the Moffitt Cancer Center and Research Institute in Tampa, Florida, presented these results at the 2011 American Society of Hematology (ASH) meeting last month.
ARRY-614 is an oral drug that is being developed by Array BioPharma. It works by preventing the death of precursor blood cells, the cells that give rise to mature blood cells. Maintaining more precursor…
Sequential treatment with Zolinza, idarubicin, and cytarabine is safe and highly effective in patients with acute myeloid leukemia and higher-risk myelodysplastic syndromes, according to results from a recent Phase 2 study.
The study authors also found that patients with mutations in the FLT-3 gene responded particularly well to the drug combination, yielding an overall response rate of 100 percent.
Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center in Houston presented these findings at the 2011 American Society of Hematology (ASH) conference in San Diego last month.
Zolinza (vorinostat), which…
Results from two independent clinical trials continue to show that myelodsyplastic syndromes patients may be effectively treated using both Vidaza and Revlimid.
Treatment with a combination of Vidaza (azacitidine) and Revlimid (lenalidomide) has previously been shown to be effective in higher-risk myelodysplastic syndromes (MDS) patients with or without chromosomal abnormalities.
The two new studies on the combined use of Vidaza and Revlimid were presented at the 2011 American Society of Hematology (ASH) meeting last month.
Phase 2 Trial: Simultaneous Treatment With Vidaza And Revlimid
Dr. Mikkael…
Results from a small Phase 2 clinical trial show that the investigational drug AR-67 is tolerable for myelodysplastic syndromes patients. However, the results also show that the drug has limited activity in these patients.
The findings were presented during a poster session at the 2011 meeting of the American Society of Hematology (ASH) in December.
AR-67 is a drug being developed by the biopharmaceutical company Arno Therapeutics for the treatment of various forms of cancer. It causes cell death by inhibiting the cell’s DNA repair mechanisms.
In this study, the…
The final results from four Phase 1/2 clinical trials of the investigational drug Estybon show that the drug is effective and safe for myelodysplastic syndromes patients.
These findings were presented during a poster sessoin at the 2011 annual meeting of the American Society of Hematology (ASH) last month.
Estybon (rigosertib, ON 01910.Na) is an investigational drug that is being developed by the pharmaceutical company Onconova Therapeutics. It works by inhibiting cell growth and selectively killing cancer cells.
Four independent Phase 1/2 trials of the efficacy and safety of Estybon in…